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Supporting Information: Lipolysis-triggered Drug Precipitation 2 (3)
All solubility samples in dispersion and digestion media, as well as drug loaded IIIB-MC lipolysis samples were analyzed by an HPLC coupled to a diode array detector (1290 Infinity with a Zorbrax Eclipse XDB-C18 column 4.6 x 100 mm, Agilent Technologies, USA). The accuracy of the HPLCanalyzes was controlled by quality control samples, prepared from a separate stock solution and recovery samples with a known concentration of drug. Prior to analysis, diluted samples were centrifuged at 22 °C, 21,000 g for 10 min. The injection volume was consistently 20 ul. Compound-specific analytical conditions are found in Table S1 . Abbreviations: acid (A); base (B); neutral in the pH range 2-12 (N), No (n), Yes (y), not determined (nd), glass-former (GF), nonglassformer (nGF), amorphous (A), crystalline (C).
Alskär et al.
Supporting Information: Lipolysis-triggered Drug Precipitation 3 (3) Figure S1 . Liberated ionized free fatty acids (FFAs) during 60 minutes of in vitro digestion (37 °C) from LBFs; IIIA-LC, IIIB-MC and IV (n =3). The IIIA-LC was digested using 4.44 ml (IIIA-LC) and 8.88 ml (IIIA-LC x2) of the pancreatic extract (n = 1). The similar FFA release profiles shows that 4.44 ml of the pancreatic extract (~ 6,600 TBU/ml extract) was sufficient for achieving complete digestion. The values have been corrected for the level of FFA released by the lipolysis media. Figure S2 . Percentage of drug in aqueous and pellet phase respectively (37 °C, pH 6.5), at 5 and 10 minutes of dispersion and 5, 30, and 60 minutes of digestion.
